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Abstract
Background: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that has been approved for the treatment
of metastatic renal cell carcinoma. Although the majority of sunitinib-treated patients receive a clinical benefit,
almost a third of the patients will not respond. Currently there is no available marker that can predict for response
in these patients.
Methods: We estimated the plasma levels of NT-pro-BNP (the N-terminal precursor of brain natriuretic peptide) in
36 patients that were treated with sunitinib for metastatic clear-cell renal carcinoma.
Results: From the 36 patients, 9 had progressive disease and 27 obtained a clinical benefit (objective response or
disease stabilization). Increases in plasma NT-pro-BNP were strongly correlated to clinical outcome. Patients with
disease progression increased plasma BNP at statistically significant higher levels than patients that obtained a
clinical benefit, and this was evident from the first 15 days of treatment (a three-fold increase in patients with
progressive disease compared to stable NT-pro-BNP levels in patients with clinical benefit, p < 0.0001). Median
progression-free survival was 12.0 months in patients with less than 1.5 fold increases (n = 22) and 3.9 months in
patients with more than 1.5 fold increases in plasma NT-pro-BNP (n = 13) (log-rank test, p = 0.001).
Conclusions: This is the first time that a potential “surrogate marker” has been reported with such a clear
correlation to clinical benefit at an early time of treatment. Due to the relative small number of accessed patients,
this observation needs to be further addressed on larger cohorts. More analyses, including multivariate analyses are
needed before such an observation can be used in clinical practice.
Background
Sunitinib is an oral, multitargeted tyrosine kinase inhibi-
tor of VEGFR-1, VEGFR-2, Fms-like tyrosine kinase
receptor 3 (FLT3), c-KIT (stem-cell factor [SCF] recep-
tor) and PDGFR [1] that has shown clinical activity in
the treatment of metastatic renal cell carcinoma. The
majority of sunitinib-treated renal cancer patients obtain
a clinical benefit in the form of either objective response
or disease stabilization (31% and 48% respectively in the
large, phase III trial [2]). Treatment with sunitinib
results in alterations of several plasma proangiogenic
factors, as sVEGFR2, VEGF, PDGF and PIGF [3]. How-
ever, none of these markers has a predictive value for
response and the search for a “surrogate marker” is still
ongoing [4].
Cardiac toxicity is reported to be a common adverse
event in sunitinib-treated patients [5]. Schmidinger et al,
reported that from 86 renal cancer patients that were
treated with sunitinib or sorafenib, 33.6% experienced a
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symptomatic [6]. On a report by Rixe and colleagues,
patients that developed hypertension during treatment
(or other sunitinib-related adverse events) had a better
outcome than normotensive ones [7], but this observa-
tion remains to be confirmed. Brain natriuretic peptide
(BNP) has been shown to be associated with left ventri-
cular dysfunction [8]. This peptide is secreted by atrial
and/or ventricular myocardial cells due to volume or
pressure overload, according to the severity of myocar-
dial dysfunction. Pro-BNP, the precursor of BNP may
provide the same diagnostic information as BNP, but
less is known about its clinical utility. Brain natriuretic
peptide (BNP) and N-terminal (NT) pro-BNP are useful
as diagnostic objective markers of chronic heart failure
(CHF) due to systolic and diastolic dysfunction and
important prognostic predictors [9].
Methods
We recently reported on a cohort of patients treated
with sunitinib for metastatic clear-cell renal carcinoma
in our department [10]. Following-up these data we
estimated the plasma levels of NT-pro-BNP in 36 suniti-
nib-treated patients as a marker for cardiac toxicity.
Sunitinib was administrated in the usual scheme (50 mg
daily, four weeks on treatment, followed by two weeks
off treatment, on a six - week cycle). During the first
two cycles, plasma was obtained every 2 weeks with a
complete blood count and a full biochemical profile. All
patients had an appropriate renal, liver, cardiac and
bone marrow function [10]. The plasma levels of
NT-pro-BNP were analyzed using Elecsys 2010 auto-
mated immunoassay analyzer. The study was approved
by the local ethics review board (Theagenion Cancer
Hospital Research and Ethics Committee) and was car-
ried out in accordance with the Declaration of Helsinki
and Good Clinical Practice Guidelines. All patients had
confirmed metastatic disease (CT and/or MRI and bone
scan), were informed for their participation and signed
the appropriate consent form.
Statistical Analysis
The Chi-square test was used for testing significance of
correlation for categorical variables. Univariate com-
parisons of Plasma NT-pro-BNP levels as well as
changes from baseline where performed with the Wil-
coxon non-parametric test. Logistic regression analysis
was used in order to assess jointly the effects of base-
line Plasma NT-pro-BNP levels and day 15 changes on
disease progression. The area under the Receiver Oper-
ating Characteristic (ROC) curve is also reported. Time
to event curves were calculated with the Kaplan-Meier
method. Indicative cutpoint determination in PFS ana-
lysis was made using the method of Contal and
O’Quigley (1999) [11] but there was no formal assess-
ment of the significance of the cutpoint due to the
small size of the sample.
Results
Data on the patient cohort are presented on table 1. At
the end of cycle 2, patients were assessed for response.
Patients that obtained a clinical benefit (CB, disease sta-
bilization or objective response according to the RECIST
criteria) remained on treatment, whilst patients with
progressive disease (PD) were discontinued. From the
36 patients, 9 had progressive disease and 27 obtained a
clinical benefit (11 had disease stabilization and 16 had
partial responses). Development of hypertension during
the first two cycles did not predict for response (37.5%
in the PD group and 40.74% in the CB group, p = 0.8).
Plasma NT-pro-BNP was increased during treatment
and did not return to baseline values during the off-
treatment period. This increase was not associated to
changes in arterial pressure or decreased left ventricular
ejection fraction, as it was assessed by echocardiogram
Table 1 Patient characteristics
Patient characteristics %
Number
Total included 36 100
Assessable for response 36 100
Sex
Male 26 72
Female 10 28
Age
Median 62
Range 25-75
Performance status
0 16 44.4
1 16 44.4
2 4 11.1
MSKCC criteria
Low risk 2 5.6
Intermediate risk 15 41.7
High risk 19 48.7
Previous treatments
Nephrectomy 30 83.3
Cytokines 15 41.7
Radiotherapy 10 27.8
Metastatic sites
Lung 24 66.7
Bone 10 27.8
Lymph nodes 7 19.4
Liver 4 11.1
Local relapse 2 5.6
Other 5 13.9
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plasma NT-pro-BNP were strongly correlated to clinical
outcome. Patients with disease progression had lower
baseline values and increased plasma BNP at statistically
significant higher levels than patients that obtained a
clinical benefit (table 2), and this was evident from the
first 15 days of treatment. Using logistic regression we
assessed the joint effect of baseline values and change at
15 days on disease progression in order to depict the
most significant predictor. Since in the logistic regres-
sion model baseline NT-pro-BNP levels were not statis-
tically significant while change at 15 days was (p-value =
0.2912 and 0.0274 respectively) it appears that the latter
has most of the information in separating the two
groups. Regression to the mean might have influenced
this result. Furthermore, the area under the ROC curve
for the change at 15 days was 94.9%, while the high cor-
relation between change at 15 days and disease progres-
sion is also depicted in figure 1 through the sharp
increase in predicted probability of disease progression
when there is an increase in plasma NT-pro-BNP levels.
Median PFS was 6.9 months in patients (n = 15) with
increases in plasma NT-pro-BNP after 15 days of treat-
ment and 15.8 months in patients (n = 20) where
plasma NT-pro-BNP remained at the baseline or lower
values (p = 0.036, log-rank test).
We further explored the effect of change at 15 days on
PFS in order to select with a statistical technique an
alternative cutpoint for grouping the patients into sepa-
rate groups. By testing several alternatives, the maxi-
mum value of the log-rank statistic was obtained at the
1.5 fold change. Median PFS (figure 2) was 3.9 months
in patients (n = 13) with more than 1.5 fold increases in
plasma NT-pro-BNP after 15 days of treatment and 12.0
months in patients (n = 22) where plasma NT-pro-BNP
showed less than 1.5 fold increases or remained at the
baseline or lower values (p = 0.001, log-rank test).
NT-pro-BNP levels in healthy population are
depended on age and gender [12]. In our cohort of
metastatic RCC patients, NT-pro-BNP levels were not
statistically significantlyd i f f e r e n ti nm e nt h a nw o m e n
and in older (> 60 years old) that younger patients. Age
and gender had no impact on the differences observed
in fold-increase of NT-pro-BNP between PD and CB
patients (Additional file 1: Table S1).
Discussion and Conclusions
Plasma NT-pro-BNP levels may reflect volume overload
or cardiac dysfunction in patients with heart disease.
We observed a high variation in pre-treatment NT-pro-
BNP levels that was not associated to disease burden or
baseline cardiac function. However, Baseline levels pre-
dicted for response and sharp increases in plasma
NT-pro-BNP were observed in patients that did not
obtain any clinical benefit from treatment, and this was
evident from the first 15 days of treatment. BNP is pro-
duced by myocardial cells, but it has been reported to
be produced by many tissues including renal parench-
yma as well [13]. Whether this observation reflects the
increasing production of NT-pro-BNP from the non-
responding metastatic foci remains yet unanswered.
When we assayed Caki-1 and Caki-2 renal cancer cell
lines in vitro we did not find any significant BNP
production and sunitinib had no effect of on BNP at a
protein level (data not shown).
On the other hand, hypoxia in large treatment-refrac-
tory tumours is a direct and sufficient stimulus for BNP
induction via stabilization of HIF-1 alpha [14]. Sunitinib
treatment results in improved blood flow and less
hypoxic tumour microenviroment [15,16] in patients
that respond. Disease progression can therefore relate to
a more hypoxic tumour environment, higher HIF-1
alpha expression, higher plasma VEGF levels (as we
have already shown, ref 10) and, finally, increased HIF-1
alpha-dependent BNP induction.
We report the value of plasma NT-pro-BNP measure-
ment for predicting response to sunitinib treatment in
patients with metastatic renal cell carcinoma. This is the
f i r s tt i m et h a tap o t e n t i a l“surrogate marker” has been
reported with such a clear correlation to clinical benefit
Table 2 Median and first and third quartile levels (pg/ml) and medianfold-increase in plasma NT-pro-BNP in patients
receiving sunitinib according to clinical outcome after the first two cycles of treatment
Baseline Actual values after baseline Median fold
change to baseline
Day15 Day30 Day45 Day75
Clinical
outcome
N Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Day15 Day30 Day45 Day75
Disease
progression
9 61.1 39.5-
120.4
132.3 75.7-
341.2
145.8 96.6-
553.3
576.8 54.5-
827.0
344.0 191.9-
1071.0
2.8 3.9 8.9 5.4
Clinical
benefit
27 149.0 97.7-
535.6
179.5 80.5-
337.5
215.2 87.4-
380.6
241.7 111.2-
555.5
260.1 120.6-
637.4
1.0 1.0 0.9 0.9
p-value 0.021 0.768 0.951 0.726 0.374 0.0002 0.002 0.003 0.025
Note: Q1 and Q3 are the first and third quartiles respectively
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Page 3 of 5Figure 1 Predicted probability of disease progression according to fold-increase in plasma NT-pro-BNP after two weeks of sunitinib
treatment. The effect of increase is statistically significant (p-value = 0.0274) but the 95% confidence limits of predicted probability are wide
due to the small size of the sample (shaded area).
Figure 2 Progression-free-survival in metastatic renal cell carcinoma patients according to fold-increase in plasma NT-pro-BNP after
two weeks of sunitinib treatment. Median PFS was 12.0 months in patients with less than 1.5 fold increases or lower or equal to baseline NT-
pro-BNP levels (n = 22) and 3.9 months in patients with more than 1.5 fold increases in plasma NT-pro-BNP (n = 13) (log-rank test, p = 0.001).
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number of assessed patients, this observation needs to
be further addressed on larger cohorts. More analyses,
including multivariate analyses are needed before such
an observation can be used in clinical practice.
Additional material
Additional file 1: Table S1. Baseline plasma NT-pro-BNP levels (pg/ml)
and medianfold ratio after 15 days of sunitinib treatment according to
age and gender. CB = Clinical benefit, PD = Progressive Disease.
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